E Fund Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$455K Sell
5,810
-2,933
-34% -$200K 0.01% 294
2026
Q1
$565K Buy
+8,743
New +$616K 0.02% 269
2025
Q2
$1.04M Buy
19,926
+9,542
+92% +$543K 0.05% 164
2025
Q1
$663K Sell
10,384
-5,002
-33% -$291K 0.03% 199
2024
Q4
$736K Buy
15,386
+3,477
+29% +$178K 0.04% 181
2024
Q3
$682K Buy
11,909
+3,955
+50% +$227K 0.04% 170
2024
Q2
$416K Sell
7,954
-2,431
-23% -$107K 0.02% 195
2024
Q1
$422K Sell
10,385
-1,638
-14% -$61.4K 0.03% 196
2023
Q4
$444K Buy
12,023
+149
+1% +$5.61K 0.03% 183
2023
Q3
$454K Sell
11,874
-1,278
-10% -$52.4K 0.03% 139
2023
Q2
$474K Buy
13,152
+3,875
+42% +$132K 0.04% 121
2023
Q1
$354K Buy
9,277
+1,850
+25% +$86.8K 0.03% 203
2022
Q4
$423K Sell
7,427
-4,078
-35% -$209K 0.04% 169
2022
Q3
$455K Buy
11,505
+1,505
+15% +$66.5K 0.04% 142
2022
Q2
$440K Buy
10,000
+2,274
+29% +$98.3K 0.04% 168
2022
Q1
$308K Buy
7,726
+2,699
+54% +$96.1K 0.01% 189
2021
Q4
$202K Buy
+5,027
New +$188K 0.01% 259

Other funds holding HALO

E Fund Management's HALO Position: Q2 2026 in Review

E Fund Management reduced its Halozyme (HALO) stake by 34% in Q2 2026, selling an estimated $200K and leaving 5,810 shares worth $455K. The position accounts for 0.01% of the portfolio, ranked #294.

E Fund Management first reported a position in HALO in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.04M in Q2 2025. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • E Fund Management held 5,810 shares of Halozyme worth $455K as of Q2 2026.
  • E Fund Management sold 2,933 Halozyme shares in Q2 2026, an estimated $200K.
  • Halozyme made up 0.01% of E Fund Management's portfolio in Q2 2026, its #294 holding.
  • E Fund Management first reported a position in Halozyme in Q4 2021 and has held it in 17 quarters since.
  • E Fund Management's Halozyme position peaked at $1.04M in Q2 2025.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.